GeneDx announced that its President and CEO, Katherine Stueland, was named to the TIME100 Health 2026 list. The recognition is one of the 100 individuals shaping global health and spotlights Stueland. For her work in rare disease diagnosis and genomics. Under her leadership. GeneDx has increased access to exome and genome sequencing, shortening the diagnostic journey for families. The company’s GeneDx Infinity™ database now represents. The world’s largest rare-disease genomic dataset, advancing precision medicine and improving patient outcomes around the world.
“Katherine’s inclusion in the TIME100 Health list reflects the growing importance. Of genomics in modern medicine and the meaningful progress GeneDx has made for patients with rare and genetic conditions. As CEO, Katherine is leading the company with a bold mission. For genomics to improve health for people around the world,” said Jason Ryan, Chairman of the GeneDx Board of Directors. “At the same time, she has built a profitable and rapidly growing business. That has elevated GeneDx as a pivotal player in the healthcare ecosystem. We are proud of Katherine’s leadership and her unwavering focus on advancing access. To genomic insights that can change the trajectory of patient care.”
Advancing Rare Disease Diagnosis and Precision Medicine
The announcement coincides with Rare Disease Month, underscoring the global focus on rare disease as a public health priority. GeneDx partners with clinicians, health systems, researchers, and policymakers. To accelerate diagnoses, enable earlier interventions, and support discovery. Recent milestones include FDA Breakthrough Device Designation for GeneDx’s exome and genome tests and new American Academy. Of Pediatrics guidance recommends genomic testing as a first-tier diagnostic tool for children with developmental delays. These developments reinforce GeneDx’s leadership in precision medicine and the transformative power of genomics in healthcare.
“Being named to the TIME100 Health is an incredible honor. But the real recognition is for the rare disease community, which rallies behind each new patient. Family who is facing a diagnosis & the journey to find a treatment or cure,” said Katherine Stueland, CEO of GeneDx. “This moment reflects a broader shift in healthcare. As genomic data, clinical insight, and policy begin to align in powerful new ways. We can move from a system that reacts to illness to one that anticipates it, ensuring every child has access. To answer from the very beginning, genomics becomes the foundational layer of lifelong health.”
“Katherine is playing a critical role in ensuring that children like my daughter, Mila, are diagnosed earlier. With greater precision,” said Julia Vitarello, CEO of EveryONE Medicines. “This is where it all begins, connecting children, diagnosed as early as birth, to a new pathway. For the rapid development of highly precise, individualized medicines. Together with Katherine’s leadership, we will prove that it’s possible. To find children early enough to stop disease before it ever begins.”
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
